Board summary
Key figures
100,887
Registered population
59.8% aged 18–64
21.6%
Aged 65+
ICB 21.9% · England 17.9%
8.3%
Ethnic minority (non-White)
2.7% Asian · England 9.6%
47.7%
In IMD quintile 1
ICB 9.2% · England 21.0%
~39,671
Core20 residents (est.)
Resident basis; registered basis ~48,556 · see page 3
17,634
Hypertension register
+8.46% in 3 yrs · England +5.60%
1,684
SMI register
100% of Hastings'
3,264
COPD register
Reviews +8.08% in 3 yrs
Forecast to 2030
21,154
Hypertension patients, 2030
+3,520 on today
73.6%
QRISK ≥20% on statins, 2030
+5.76pp over 3 yrs
6.1%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Asthma annual reviews fell while England rose.
Coverage is 60.2% (England 65.7%) after changing by -4.3% over 2023 to 2025 (England +4.4%), leaving about 2,600 patients unreviewed, which may reflect recall.
Early MMR uptake trails the 95% target.
In Q1 2025/26, 24-month MMR dose 1 coverage is 83.1% (England 88.3%, -11.9 pp to the 95% target), alongside a 6 pp age-five dose.
Primary prevention statin prescribing outpaced national growth.
Statin treatment in diabetes without CVD grew +7.5% over 2023 to 2025 (England +2.1%), reaching 76.1% against 73.2% in England.
Population, age and ethnicity
Over a fifth of patients are aged 65+, exceeding England by 3.7 percentage points
Across 100,887 registered patients, 21.6% (21,789) are aged 65+, compared with 19.8% in Hastings, 21.9% in NHS Sussex Integrated Care Board and 17.9% in England. Registered patients aged 18-64 represent 59.8% (60,314) and aged 0-17 represent 18.6% (18,784). Ethnicity data reflect Census usual residents, not registered patients: 91.7% are White against 91.4% in Hastings, 91.0% in NHS Sussex Integrated Care Board and 81.1% in England, giving an 8.3% ethnic minority share. Projected list growth to 2030 is 1.0% (Hastings 1.0%, NHS Sussex Integrated Care Board 2.1%, England 2.3%), with unverified projection methodology.
Age profile
65+: ICB 21.9%, England 17.9%
Ethnicity
Older people · falls rows are Hastings local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Hastings LA) | 2,494 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 81.8% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 56.3% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Hastings LA) | 1,236 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Hastings LA) | 10.6 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 share reaches 47.7%, spanning 51.0 pp between practices across the PCN
Across the PCN, 47.7% of registered patients live in Core20 areas, compared with 49.5% in Hastings, 9.2% in NHS Sussex Integrated Care Board, and 21.0% in England. Practice share spans 51.0 pp, from 26.2% at The Hill Surgery to 77.2% at Priory Road Surgery, though Hastings Old Town Surgery holds the highest volume (14,904 estimated patients). Denominators must be reconciled before targeting: practice estimates sum to 48,556 registered patients, whereas the resident estimate for deciles 1 and 2 is 39,671.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
1,684
SMI register
1.66% recorded prevalence
905
Learning disability register
0.89% recorded prevalence
65
Care homes, 1,541 beds
In the PCN catchment
9.9%
Provide unpaid care
Hastings, Census 2021
Severe mental illness prevalence is 1.7% (1,684 patients; Hastings 1.7%, NHS Sussex Integrated Care Board 1.1%, England 1.0%) and learning disability is 0.9% (905 patients; England 0.6%). Catchment data show 65 care homes (1,541 beds); borough homelessness (37 rough sleepers) and carer ceiling estimates (about 10,000) are local authority figures. Higher recorded SMI and learning disability prevalence than England suggests proactive annual reviews and care-home coordination as potential inclusion priorities.
Severe mental illness: physical health checks
Severe mental illness prevalence is 1.7% (England 1.0%). Recorded blood pressure checks reached 80.4% (England 83.4%) and BMI checks reached 78.0% (England 82.1%). Metabolic monitoring trailing England benchmarks may indicate recall gaps to test through practice audits.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
17,634
Hypertension register
+8.46%
Register growth, 3 yrs
Hastings +6.16% · England +5.60%
+3.98pp
BP control, under 80
≤140/90 · +0.70pp aged 80+
+3,520
More patients by 2030
Forecast 21,154 (20.45%)
Hypertension case-finding and control
Recorded hypertension prevalence is 17.4% (17,634 patients), above England (15.2%) and NHS Sussex Integrated Care Board (16.3%), with three-year growth of +8.5% (England +5.6%). However, blood pressure control for patients aged 80 and over is 77.1%, trailing England (81.2%) and NHS Sussex Integrated Care Board (79.2%). For patients under 80, control reaches 66.4% (England 67.8%). Crude prevalence is unadjusted for age. Lower blood pressure control among older patients could reflect medication review gaps, testable via clinical audit.
Lipids and statins
Patients with QRISK ≥ 20% receiving lipid-lowering therapy reach 60.2%, below England (63.6%) though in line with NHS Sussex Integrated Care Board (60.0%). Secondary prevention in diabetes reaches 81.3% (England 84.4%). Lower coverage than England may indicate treatment recall gaps to test through clinical audit.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 220,234 | £1.90 | £2.42 | £1.86 | £418,445 |
| Cardiovascular (all), 2025 | 277,365 | £2.97 | £3.32 | £3.33 | £823,774 |
In 2026, 220,234 items of lipid-regulating drugs were prescribed at £1.90 per item (spend £418,445; England £1.86, NHS Sussex Integrated Care Board £2.42). The PCN spent £8,809 more than at England's unit cost, but £114,522 less than at the ICB unit cost. Unit-cost differences could reflect formulary choices to test via prescribing review.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−4.31%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+4.36%
Asthma prevalence, PCN 3-yr % change
Asthma prevalence is 6.8% (England 6.6%), but reviews fell 4.3% over 2023 to 2025 (England +4.4%) to 60.2% (England 65.7%), leaving about 2,600 patients on the 6,554 register unreviewed. For ages 6–19, second-hand smoke recording is 69.3% (England 78.8%), with 2,214 asthma items prescribed per 1,000 population aged 5–19 (England 1,488). COPD prevalence is 3.2% (England 1.9%) with reviews rising +8.1% (England +2.8%) to 74.6% (England 76.4%). Trailing reviews may indicate recall gaps to test through practice audits.
Cancer register and children's immunisation
Cancer prevalence is 4.6% (4,624 patients; England 3.8%). In Q1 2025/26, MMR1 coverage at 24 months is 83.1%, falling below the 95.0% target by 11.9 pp (England 88.3%). At age 5, MMR1 coverage reaches 92.1% while MMR2 drops to 86.1%, showing a 6 pp dose gap. Coverage below targets may reflect call-recall delays, testable through practice audits.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
58.5%
Sussex ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~1,360
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Sussex ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Prostate | 56.6% | 53.2% | 19% | 1,668 |
| Breast | 86.1% | 85.4% | 23% | 1,400 |
| Bowel | 49.8% | 47.0% | 26% | 1,133 |
| Lung | 30.3% | 33.8% | 15% | 1,058 |
| Skin cancer | 95.3% | 87.8% | 17% | 698 |
In 2022, 58.5% of staged cancers across NHS Sussex ICB were diagnosed at stage 1 or 2 (4,799 of 8,209 known-stage cases; England 55.3%), sitting 16.5 pp below the 75.0% national ambition. Known-stage completeness was 64.3% (8,209 of 12,766 registered cases; England 67.0%). About 1,360 additional early-stage diagnoses a year are needed across the ICB to reach 75%. Within the PCN, cervical screening (25-49 yrs) is 66.3% (NHS Sussex Integrated Care Board 68.6%), with The Station Practice at 60.6% and Hastings Old Town Surgery at 63.0%. Prioritising screening uptake in lower-coverage practices may help identify earlier lesions and support broader system diagnosis ambitions.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
At East Sussex Healthcare NHS Trust, cancer 62-day referral to treatment was 18.0 pp below the 85.0% standard (67.0418%). The trust met the 28-day faster diagnosis standard at 84.1975% (9.2 pp above the 75.0% standard) and 31-day combined treatment at 98.1873% (2.2 pp above the 96.0% standard). Across NHS Surrey and Sussex Integrated Care Board, 62-day referral to treatment was 13.5 pp below the 85.0% standard (71.5074%), 28-day faster diagnosis was 79.2873% (4.3 pp above 75.0%) and 31-day treatment was 90.4462% (5.6 pp below 96.0%). These secondary care metrics describe wider system performance.
| Pathways within standard (%) | East Sussex Healthcare | Maidstone and Tunbridge Wells | East Kent | Surrey and Sussex ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 84.20 | 81.78 | 71.28 | 79.29 | 79.32 |
| 31-day treatment (96%) | 98.19 | 98.35 | 96.67 | 90.45 | 92.50 |
| 62-day referral to treatment (85%) | 67.04 | 87.43 | 70.01 | 71.51 | 71.16 |
| Diagnostic waits over 6 weeks (%) | East Sussex Healthcare | Maidstone and Tunbridge Wells | East Kent | England |
|---|---|---|---|---|
| MRI | 6.48 | 0.92 | 47.58 | 21.40 |
| CT | 0.48 | 0.51 | 37.45 | 9.92 |
| Echocardiography | 21.94 | 2.57 | 14.17 | 28.48 |
| Colonoscopy | 0.74 | 19.80 | 9.58 | 30.83 |
| Gastroscopy | 0.31 | 24.03 | 22.16 | 29.02 |
| All 15 DM01 tests | 5.27 | 6.42 | 48.38 | 23.14 |
| Community services activity | East Sussex residents | Surrey and Sussex ICB |
|---|---|---|
| Care contacts | 100,740 | 309,615 |
| Referrals | 17,285 | 66,930 |
| Patients with a contact | 25,880 | 85,660 |
Community services (residents of East Sussex), Jun 2026 (provisional). In provisional Jun 2026 Community Services Data Set records, 68% of community contacts for Hastings borough residents were with adults aged 65+ (68,465 of 100,740 contacts). No community provider was captured. Borough-level community contacts describe local system activity outside primary care.
Practice variation and patient experience
Practice variation and patient experience
Across 2025/26, overall QOF achievement for England was 92.5%. Across practices, overall achievement ranged from 75.9% at High Glades Medical Centre to 98.7% at South Saxon House Surgery. In the vaccination and immunisation domain, achievement spanned 73.1 pp, from 15.6% at The Station Practice to 88.8% at South Saxon House Surgery, compared to England at 55.2%.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Priory Road | 108 | 77.2 | 74.6% | 69.8% | 88.7% |
| Carisbrooke | 122 | 53.1 | 69.2% | 83.8% | 86.6% |
| South Saxon House | 124 | 41.4 | 75.2% | 57.6% | 84.4% |
| Sedlescombe House | 106 | 38.5 | 89.8% | 61.6% | 84.2% |
| High Glades | 106 | 39.6 | 48.4% | 55.7% | 76.5% |
| Station | 104 | 61.1 | 26.7% | 70.9% | 67.3% |
| The Hill Surgery | 127 | 26.2 | 27.7% | 67.3% | 62.5% |
| Hastings Old Town | 103 | 58.7 | 12.8% | 60.8% | 61.3% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Three-year progress trails England across 8 clinical measures, led by annual reviews
Between 2023 and 2025, heart failure reviews changed -0.1% (England +8.7%; NHS Sussex Integrated Care Board +4.5%) to 74.2% (England 78.5%), and asthma reviews changed -4.3% (England +4.4%; NHS Sussex Integrated Care Board +4.8%) to 60.2% (England 65.7%). Severe mental illness checks also lagged: BMI recording rose +0.2 pp (England +5.1 pp) to 78.0%, and blood pressure checks rose +1.4 pp (England +4.4 pp) to 80.4%. Strengths included diabetes statin treatment (+7.5% vs England +2.1%) and breast screening (+13.8% vs England +8.4%, 2023 to 2024).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
Asthma reviews
Alcohol record (psychosis)
BMI record (SMI)
BP check (SMI)
Breast screening (53-70)
Diabetes statin (no CVD)
COPD reviews
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Hastings | Asset | PCN | Hastings |
|---|---|---|---|---|---|
| Care homes (catchment) | 65 (1,541 beds) | n/a | Schools (catchment) | 76 | n/a |
| Children's centres | 4 | 4 | Places of worship | 62 | 51 |
| Libraries | 3 | 3 | Food banks (VCS) | 1 | 1 |
| Homelessness support (VCS) | 0 | no data | Day centres (VCS) | 5 | 5 |
| Children and young people (VCS) | 1 | 1 | Carers support groups (VCS) | 1 | 1 |
| Primary schools (LA maintained) | 5 | 2 | Primary academies | 14 | 14 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma review and recall
Asthma reviews fell 4.3% (2.7 pp) over 2023 to 2025 to 60.2% (England 65.7%, +4.4%), leaving 2,611 (about 2,600) of 6,554 patients unreviewed; ages 6-19 second-hand smoke recording is 69.3% (England 78.8%). Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Combined SMI physical health checks
Across 1,684 SMI register patients (1.7% vs England 1.0%), annual BP checks are 80.4% (England 83.4%; +1.4 pp vs +4.4 pp, 2023 to 2025) and BMI recording is 78.0% (England 82.1%; +0.2 pp vs +5.1 pp). Moderate effort to run.
Evidence base: the SMI register is the cohort for the annual physical health check; the alcohol record is the delivery measure for alcohol screening and brief intervention.
Policy anchor: Mental Health Investment Standard; NHS alcohol care teams and the From Harm to Hope strategy.
Option 3
Older hypertension and lipid recall
On the 17,634 hypertension register (17.4% vs England 15.2%), 80+ BP control is 77.1% (England 81.2%; +0.9% vs +2.2%, 2023 to 2025), and QRISK ≥ 20% lipid therapy is 60.2% (England 63.6%). Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Older adult service alignment (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Two-track Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical check recall audit (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Older hypertensive blood pressure review (p5) | Last BP reading of patients (80+ yrs with hypertension) in the last 12 months is <= 150/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Childhood immunisation call-recall audit (p6) | MMR dose 1 coverage at 24 months | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Option 1 · Structured asthma review and recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Patients with Asthma (6-19 yrs): Second-hand smoking status recorded in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · Combined SMI physical health checks (p12) | Severe mental illness register · Severe mental illness: QOF prevalence · SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Option 3 · Older hypertension and lipid recall (p12) | Hypertension register · Hypertension: QOF prevalence · Last BP reading of patients (80+ yrs with hypertension) in the last 12 months is <= 150/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
